Pfizer Inc. (NYSE:PFE) is included among the 13 Best January Dividend Stocks to Invest in. Pfizer Inc. (NYSE:PFE) is among ...

Now, it’s worth noting Stock Advisor’s total average return is 966 % — a market-crushing outperformance compared to 194% for ...

More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers ...

Pfizer Inc. (NYSE:PFE) ranks among the best stocks under $25 to buy now. Citing the company’s cautious 2026 outlook, BMO ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

The New York Times once called John Lamattina, then Pfizer head of R&D, “Dr. Optimistic.” He’s not so optimistic now.

By the beginning of 2025, it was clear the GLP-1 drugs were going to remain a major part of the industry. Pfizer used its presentation at the 43 rd JP Morgan Healthcre Conference to detail plans to ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing ...

Texas Attorney General Ken Paxton is suing Pfizer and drug manufacturer Tris Pharma for fraud, alleging they provided “adulterated” attention deficit disorder medications to underprivileged children ...

The patient, who died on December 14, was originally enrolled in a Phase III study in 2022 and transitioned into an extension phase in 2023.